GET THE APP

Response to PARP Inhibitor in PALB2-Mutated Metastatic Pancreatic Adenocarcinoma: A Case Report

Clinical Oncology: Case Reports.

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Response to PARP Inhibitor in PALB2-Mutated Metastatic Pancreatic Adenocarcinoma: A Case Report

Abstract

PALB2 (Partner and Localizer of Breast Cancer Type 2 (BRCA2)) pathogenic variants increase sensitivity to poly (ADP-ribose) Polymerase Inhibitors (PARPi) in a variety of malignancies, yet no documented objective response to treatment in metastatic pancreatic cancer has been reported. We describe a case of a PALB2-mutated metastatic pancreatic cancer patient who had achieved a partial response to platinum-based chemotherapy, and was then observed to achieve an ongoing partial response with a further 42% reduction in tumor size over 6-months of treatment to date whilst on the PARPi olaparib.

Special Features

Full Text

View

Track Your Manuscript

Media Partners

Associations